Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer

Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer
Second preliminary results from the FOCUS Phase 2/3 trial assessing the safety and effectiveness of Mateon Therapeutics’ drug candidate CA4P in combination with standard-of-care therapies for platinum-resistant ovarian cancer are expected in coming months, the company announced. CA4P (combretastatin a4-phosphate), also known as fosbretabulin, was designed to target blood vessels and blood supply within tumors. This

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *